# A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

> **NCT03828747** · PHASE2 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 272 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Semorinemab
- **DRUG:** Placebo
- **DRUG:** [18F]GTP1

## Key facts

- **NCT ID:** NCT03828747
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-25
- **Primary completion:** 2021-07-20
- **Final completion:** 2023-08-30
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2024-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03828747

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03828747, "A Study of Semorinemab in Patients With Moderate Alzheimer's Disease". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT03828747. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*